STERNA BIOLOGICALS GmbH

sterna biologicals is a clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as atopic dermatitis, ulcerative colitis, asthma and chronic obstructive pulmonary disease (COPD). By targeting GATA-3, a key master transcription factor that plays a central role in chronic inflammatory diseases, the company’s proprietary DNAzyme-based drug candidate, hgd40, antagonizes several inflammatory processes and mediators. sterna biologicals has completed multiple phase IIa clinical trials with hgd40 in a number of commercially attractive chronic inflammatory diseases with high unmet medical need. If you are interested in partnering with us, please reach out at partnering@sterna-biologicals.com.